ARTICLE | Clinical News
anti-CD11a (hu1124): Completed Phase I/II trial enrollment
November 20, 2000 8:00 AM UTC
Xoma Ltd. (XOMA), Berkeley, Calif. Product: anti-CD11a (hu1124) Business: Transplant Therapeutic category: Antibody, Immune suppression Target: CD11a receptor on T cells Description: Recombinant human...